2230777-09-8
Chemical Structure
Taccalonolide AJ
- CAS No.: 2230777-09-8
- Formula:C34H44O14
- Molecular Weight:676.70
IUPAC Name: (1S,3aS,4aS,5S,5aS,5bR,6R,7S,7aS,7bR,8R,8aS,9aS,10aS,12R,12aS,12bS,13R,13aR,13bS)-1,12,13-trihydroxy-1,5,5b,7b,13b-pentamethyl-2,11-dioxodocosahydrooxireno[2',3':2,3]oxireno[2'',3'':6',7']naphtho[1',2':7,8]fluoreno[2,1-b]furan-6,7,8-triyl triacetate
InChIKey: BWKYBGRKQMTOQL-MPOFNYKTSA-N
SMILES: C[C@]1([C@@]2(O)C)[C@]3(OC2=O)[C@H]([C@@H](C)[C@@]4([H])[C@@]1([H])[C@@H]([C@]5([H])[C@@]4([C@H]([C@@H](OC(C)=O)[C@@]6([H])[C@@]5([H])[C@H](C([C@]7([H])[C@@]6([C@H]([C@@H](O8)[C@@H]8C7)OC(C)=O)C)=O)O)OC(C)=O)C)O)O3
Biological Activity: Taccalonolide AJ is a microtubule stabilizer and antiproliferative agent with an IC50 of 4.2 nM against β-tubulin (β-tubulin) D226. Taccalonolide AJ increases cellular microtubule density, induces microtubule bundling, triggers G2/M cell cycle arrest with abnormal mitotic spindles, and inhibits cancer cell proliferation. Taccalonolide AJ can be used in the research of oral cancer, breast cancer, solid tumors, as well as tumors resistant to Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A)[1][2][3][4][5][6][7].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Taccalonolide AJ | 98.6% | Taccalonolide AJ is a microtubule stabilizer and antiproliferative agent with an IC50 of 4.2 nM against β-tubulin (β-tubulin) D226. Taccalonolide AJ increases cellular microtubule density, induces microtubule bundling, triggers G2/M cell cycle arrest with abnormal mitotic spindles, and inhibits cancer cell proliferation. Taccalonolide AJ can be used in the research of oral cancer, breast cancer, solid tumors, as well as tumors resistant to Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Li J, et al. Potent taccalonolides, AF and AJ, inform significant structure-activity relationships and tubulin as the binding site of these microtubule stabilizers. Journal of the American Chemical Society. 2011 Nov 30;133(47):19064-7. [Content Brief]
- [2]. Risinger AL, et al. Pharmacokinetic Analysis and in Vivo Antitumor Efficacy of Taccalonolides AF and AJ. Journal of natural products. 2017 Feb 24;80(2):409-414. [Content Brief]
- [3]. Yee SS, et al. Taccalonolide Microtubule Stabilizers. Prog Chem Org Nat Prod. 2020;112:183-206.
- [4]. Du L, et al. Elucidating target specificity of the taccalonolide covalent microtubule stabilizers employing a combinatorial chemical approach. Nature communications. 2020 Jan 31;11(1):654.
- [5]. Wang Y, et al. Mechanism of microtubule stabilization by taccalonolide AJ. Nature communications. 2017 Jun 06;8:15787.
- [6]. Chen X, et al. Taccalonolides: A Novel Class of Microtubule-Stabilizing Anticancer Agents. Cancers. 2021 Feb 22;13(4):920.
- [7]. Risinger AL, et al. Taccalonolide binding to tubulin imparts microtubule stability and potent in vivo activity. Cancer research. 2013 Nov 15;73(22):6780-92.
